Abstract

 CADTH recommends that Keytruda be reimbursed by public drug plans for the treatment of adult patients with high-risk early-stage triple-negative breast cancer (TNBC) in combination with chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery only if certain conditions are met.
 Keytruda should only be covered for adult (18 years of age or older) patients with early-stage TNBC who are at high risk for breast cancer coming back.
 Keytruda should only be used with chemotherapy before surgery, then alone after surgery. Keytruda should only be reimbursed if: prescribed by a specialist, if the patient is in relatively good health (i.e., have a good performance status, as determined by a specialist), the patient has not received prior systemic therapy for non-metastatic TNBC; and the patient has no clinical contraindication to immunotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
